Get the Stockscreener App
7.39
2.25%
-0.17
Pre-market:
7.50
0.11
+1.49%
Vanda Pharmaceuticals Inc stock is traded at $7.39, with a volume of 887.79K.
It is down -2.25% in the last 24 hours and up +5.57% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$7.56
Open:
$7.56
24h Volume:
887.79K
Relative Volume:
0.38
Market Cap:
$444.40M
Revenue:
$216.11M
Net Income/Loss:
$-220.47M
P/E Ratio:
-1.9779
EPS:
-3.7363
Net Cash Flow:
$-110.44M
1W Performance:
+8.04%
1M Performance:
+5.57%
6M Performance:
+66.44%
1Y Performance:
+61.00%
1-Day Range:
$7.35
$7.58
1-Week Range:
$6.80
$7.59
52-Week Range:
$3.8092
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
7.39 | 444.40M | 216.11M | -220.47M | -110.44M | -3.7363 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Initiated | Truist | Buy |
| Nov-05-25 | Initiated | B. Riley Securities | Buy |
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Vanda Pharmaceuticals (VNDA) Launches Nereus for Motion Sickness Relief - GuruFocus
Vanda Pharmaceuticals shares rise on Nereus commercial launch By Investing.com - Investing.com Australia
D.C.'s Vanda Pharmaceuticals launches first new prescription motion sickness drug in decades - The Business Journals
Vanda launches motion sickness drug after 40-year gap By Investing.com - Investing.com South Africa
Vanda launches motion sickness drug after 40-year gap - Investing.com
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus(TM) (tradipitant), the first new pharmacologic treatment for people with motion sickness in more than 40 years - marketscreener.com
Vanda Pharmaceuticals Announces U.S. Commercial Availability Of Nereus™ (Tradipitant), The First New Pharmacologic Treatment For People With Motion Sickness In More Than 40 Years - TradingView
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Pharmaceuticals (VNDA) Launches Nereus for Motion Sickness Prevention - GuruFocus
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years - The Malaysian Reserve
Vanda Pharmaceuticals (VNDA) Launches New Motion Sickness Drug, Stock Rises - GuruFocus
NEREUS now available for online purchase as Vanda Pharmaceuticals expands access - Traders Union
MSN Money - MSN
Gastroparesis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market: Investment-Ready Growth Trends to 2034 - openPR.com
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
VNDA Stock Price, Quote & Chart | VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) - ChartMill
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - BioSpace
Vanda Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Vanda sets May 6 earnings release, investor call after market close - Stock Titan
BlackRock (NASDAQ: VNDA) reports 2.5M shares beneficially owned in 13G/A - Stock Titan
Vanda Pharmaceuticals (VNDA) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
VNDA Q1'26 Earnings: revenue estimate is 54.98M USD - TradingView
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - The Malaysian Reserve
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings - Intellectia AI
Vanda Sues FDA Over Suspended Drug Study for Stomach Disorder - Bloomberg Law News
Vanda Pharmaceuticals announces the publication of "Efficacy and - GuruFocus
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
The Christmas party is still ongoing in these stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - MSN
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
HC Wainwright & Co. Reiterates Vanda Pharmaceuticals (VNDA) Buy Recommendation - MSN
Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia - MSN
Vanda Pharmaceuticals (VNDA) grants director 57,101 time-based RSUs - Stock Titan
Vanda Pharmaceuticals (NASDAQ: VNDA) director files initial Form 3 ownership - Stock Titan
Vanda Pharmaceuticals | DEFA14A: Others - Moomoo
Vanda Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
[ARS] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
Executive pay, board votes and pipeline in Vanda (NASDAQ: VNDA) 2026 proxy - Stock Titan
Vanda Pharmaceuticals adds Charles Duncan to board By Investing.com - Investing.com India
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board o - GuruFocus
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to Board of Directors to Drive Growth and Innovation in CNS Therapies 1 - Minichart
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):